The company's mission is to discover and develop small molecules that modulate mitophagy and autophagy, critical neural pathways that degrade toxic cellular components, to restore cellular balance and prevent neurodegenerative diseases. By targeting lysosomes, Rheostat's treatments aim to modulate and restore their activity, providing physicians with a tool to improve the lives of patients suffering from a range of neurodegenerative diseases and senescence.